期刊
CURRENT CANCER DRUG TARGETS
卷 23, 期 5, 页码 354-362出版社
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1568009623666221115095114
关键词
cGAS-STING; lung cancer; immunotherapy; combination therapy; STING agonist; cGAMP
类别
Immunotherapy has revolutionized lung cancer treatment and improved overall survival for advanced patients, but many are still resistant. The cGAS-STING pathway has shown potential in overcoming resistance and enhancing antitumor immunity, making it a promising target for new therapies.
Immunotherapy has completely changed the treatment pattern of lung cancer and significantly prolonged the overall survival of patients, especially for advanced patients. However, a large number of lung cancer patients are unable to benefit from immunotherapy, which forces us to find new therapeutic targets to overcome drug resistance to immunotherapy. Cyclical GMP-AMP synthetase (cGAS) recognizes cytoplasmic DNA and promotes the formation of cyclical GMP-AMP (cGAMP), activates stimulator of interferon genes (STING), then induces the expression of varieties pro-inflammatory cytokines and chemokines, and then promotes the cross-presentation of dendritic cells (DCs) and initiates tumor-specific CD8+T cell response, showing great potential to overcome resistance and enhance antitumor immunity. In this review, we describe recent advances in the biological function,activation mode, and current applications of cGAS-STING pathway in lung cancer therapy. We also describe the mechanisms of the inactivation of cGAS-STING pathway in lung cancer cells, hoping to promote the progress of immunotherapy of lung cancer by targeting cGAS-STING pathway.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据